Crohns Disease

Immunology
4
Pipeline Programs
5
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 5 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Teva
TevaIsrael - Petach Tikva
2 programs
1
1
glatiramer acetatePhase 21 trial
Delayed Release 6 mercaptopurinePhase 11 trial
Active Trials
NCT00774982Completed12Est. Feb 2009
NCT00731172Unknown50Est. Jul 2011
Tr1X
Tr1XCA - San Diego
1 program
1
TRX103Phase 1/21 trial
Active Trials
NCT06721962RecruitingEst. Jan 2027
Celularity
CelularityFLORHAM PARK, NJ
1 program
1
PDA001Phase 11 trial
Active Trials
NCT01769755CompletedEst. Nov 2014
UP
UCB PharmaBelgium - Brussels
2 programs
CertolizumabN/AMonoclonal Antibody1 trial
Exam under anesthesiaN/A1 trial
Active Trials
NCT01582568Terminated1Est. Mar 2014
NCT01145365Completed21Est. Jun 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Tevaglatiramer acetate
Tr1XTRX103
CelularityPDA001
TevaDelayed Release 6 mercaptopurine
UCB PharmaCertolizumab
UCB PharmaExam under anesthesia

Clinical Trials (6)

Total enrollment: 84 patients across 6 trials

NCT00731172Tevaglatiramer acetate

A Double Blind Placebo Control Study to Assess the Safety,Tolerability and Efficacy of Copaxone in Crohn's Disease

Start: Sep 2008Est. completion: Jul 201150 patients
Phase 2Unknown
NCT06721962Tr1XTRX103

Treatment of Moderate to Severe Refractory Crohn's Disease

Start: May 2025Est. completion: Jan 2027
Phase 1/2Recruiting
NCT01769755CelularityPDA001

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

Start: Mar 2013Est. completion: Nov 2014
Phase 1Completed
NCT00774982TevaDelayed Release 6 mercaptopurine

Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients

Start: Dec 2008Est. completion: Feb 200912 patients
Phase 1Completed
NCT01582568UCB PharmaCertolizumab

EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment

Start: Jun 2011Est. completion: Mar 20141 patients
N/ATerminated
NCT01145365UCB PharmaExam under anesthesia

Study to Look at Benefit of Surgical Drainage Before Beginning Medical Therapy for Crohns Perianal Fistulas

Start: Dec 2010Est. completion: Jun 201521 patients
N/ACompleted

Related Jobs in Immunology

Regulatory Affairs Manager(Immunology), Korea

AbbVie
Seoul, Seoul
8h ago

Regional Sales Trainer - Rheumatology (Mid Atlantic/Central)

AbbVie
Remote
9h ago

Senior Area Business Specialist, Immunology - Detroit, MI - Johnson & Johnson Innovative Medicine

Johnson & Johnson
Detroit, Michigan, United States
23h ago

Product Specialist - Immunology

Johnson & Johnson
Kibbutz Shefayim, Center District, Israel
23h ago

Senior Clinical Trial Physician, Rheumatology

Bristol Myers Squibb
Princeton - NJ - US
23h ago
$309K - $374K/yr

Supply Chain and Procurement Controller

Ferring Pharmaceuticals
Hvidovre, Denmark
23h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 84 patients
5 companies competing in this space

Related Indications

Rheumatoid Arthritis(475)Psoriasis(206)Ulcerative Colitis(151)Atopic Dermatitis(144)Crohn's Disease(140)Systemic Lupus Erythematosus(85)Arthritis, Rheumatoid(61)Plaque Psoriasis(53)Crohn Disease(49)Ankylosing Spondylitis(33)